Increased levels of plasma haemoxygenase-1 in prostate cancer.

Andrew Blann, B Balakrishnan, Philip Ryan, Gregory Lip

Research output: Contribution to journalArticle

6 Citations (Scopus)


Angiogenesis, a key component of cancer, may be driven by angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-2. Haemoxygenase-1 (HO-1), a haem-degrading enzyme, may have alternative roles in angiogenesis. Levels of plasma HO-1 have not been reported in prostate cancer. We tested the hypothesis of abnormal HO-1 in 30 men with early prostate cancer, compared with 22 men with benign prostate disease (BPD) and 26 men free of prostate disease, and that HO-1 levels would correlate with VEGF, angiopoietin-2, von Willebrand factor (vWf, marking endothelial perturbation) and PSA. Plasma HO-1 was twofold higher in prostate cancer than in the two control groups, while vWf, VEGF and PSA were also raised (all P0.5, P
Original languageEnglish
Pages (from-to)114-7
Number of pages4
JournalProstate Cancer and Prostatic Diseases
Issue number2
Publication statusPublished - 1 Jun 2011


Dive into the research topics of 'Increased levels of plasma haemoxygenase-1 in prostate cancer.'. Together they form a unique fingerprint.

Cite this